{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T16:30:55Z","timestamp":1718209855462},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0149293","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T18:43:00Z","timestamp":1455302580000},"page":"e0149293","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma"],"prefix":"10.1371","volume":"11","author":[{"given":"Corinna","family":"Seliger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph R.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan S.","family":"Jick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Bogdahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Leitzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"R Stupp","year":"2009","journal-title":"The lancet oncology"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/oxfordjournals.epirev.a036200","article-title":"Etiology of brain tumors in adults","volume":"17","author":"PD Inskip","year":"1995","journal-title":"Epidemiologic reviews"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-011-0662-x","article-title":"The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway","volume":"106","author":"GR Sareddy","year":"2012","journal-title":"Journal of neuro-oncology"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuint.2011.06.018","article-title":"COX-2 regulates the proliferation of glioma stem like cells","volume":"59","author":"V Sharma","year":"2011","journal-title":"Neurochemistry international"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2008.07.014","article-title":"TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin","volume":"442","author":"T Gaiser","year":"2008","journal-title":"Neuroscience letters"},{"issue":"4B","key":"ref6","first-page":"2547","article-title":"Celecoxib increased expression of 14-3-3sigma and induced apoptosis of glioma cells","volume":"27","author":"JC Chen","year":"2007","journal-title":"Anticancer research"},{"issue":"1","key":"ref7","first-page":"7","article-title":"Combination celecoxib and temozolomide in C6 rat glioma orthotopic model","volume":"15","author":"SG Kang","year":"2006","journal-title":"Oncology reports"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4161\/cbt.3.1.571","article-title":"Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines","volume":"3","author":"A Kardosh","year":"2004","journal-title":"Cancer biology & therapy"},{"issue":"2","key":"ref9","first-page":"263","article-title":"Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib","volume":"11","author":"DH Nam","year":"2004","journal-title":"Oncology reports"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/neuonc\/not062","article-title":"Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress","volume":"15","author":"K Suzuki","year":"2013","journal-title":"Neuro-oncology"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3171\/2009.11.JNS091396","article-title":"Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation","volume":"114","author":"HI Ma","year":"2013","journal-title":"Journal of neurosurgery"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/09553000701558985","article-title":"Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration","volume":"83","author":"GK Kuipers","year":"2007","journal-title":"International journal of radiation biology"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-007-9385-4","article-title":"Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells","volume":"85","author":"IV Bijnsdorp","year":"2007","journal-title":"Journal of neuro-oncology"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ijrobp.2006.09.055","article-title":"Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis","volume":"67","author":"KB Kang","year":"2007","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"6","key":"ref15","first-page":"2513","article-title":"Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor","volume":"6","author":"C Petersen","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00262-014-1561-8","article-title":"Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells","volume":"63","author":"A Kosaka","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"NJ Robison","year":"2014","journal-title":"Pediatric blood & cancer"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/tlo.08160","article-title":"COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature","volume":"2","author":"M Wagemakers","year":"2009","journal-title":"Translational oncology"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-004-0620-5","article-title":"Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme","volume":"131","author":"J Tuettenberg","year":"2005","journal-title":"Journal of cancer research and clinical oncology"},{"issue":"1\u20132","key":"ref20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2014.06.019","article-title":"Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory","volume":"274","author":"S Eberstal","year":"2014","journal-title":"Journal of neuroimmunology"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3727\/096504013X13685487925176","article-title":"Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model","volume":"20","author":"H Zhang","year":"2013","journal-title":"Oncology research"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/ijc.28607","article-title":"Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors","volume":"134","author":"S Eberstal","year":"2014","journal-title":"International journal of cancer"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-011-1196-y","article-title":"Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors","volume":"61","author":"S Eberstal","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.18632\/oncotarget.358","article-title":"Pilot study of a pediatric metronomic 4-drug regimen","volume":"2","author":"N Andre","year":"2011","journal-title":"Oncotarget"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/neuonc\/noq100","article-title":"A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and\/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma","volume":"12","author":"MR Gilbert","year":"2010","journal-title":"Neuro-oncology"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11060-010-0313-7","article-title":"Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma","volume":"102","author":"T Walbert","year":"2011","journal-title":"Journal of neuro-oncology"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11060-010-0192-y","article-title":"Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma","volume":"100","author":"F Stockhammer","year":"2010","journal-title":"Journal of neuro-oncology"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1215\/15228517-2008-005","article-title":"Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults","volume":"10","author":"S Kesari","year":"2008","journal-title":"Neuro-oncology"},{"issue":"1\u20132","key":"ref29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000120028","article-title":"Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas\u2014a phase II study","volume":"73","author":"P Hau","year":"2007","journal-title":"Oncology"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1215\/15228517-2007-006","article-title":"Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults","volume":"9","author":"S Kesari","year":"2007","journal-title":"Neuro-oncology"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11060-005-9062-4","article-title":"Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme","volume":"78","author":"VA Levin","year":"2006","journal-title":"Journal of neuro-oncology"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cncr.20776","article-title":"Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma","volume":"103","author":"DA Reardon","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","article-title":"COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells","volume":"71","author":"M Fujita","year":"2011","journal-title":"Cancer research"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s10552-013-0279-9","article-title":"Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within the Clinical Practice Research Datalink","volume":"24","author":"FJ Bannon","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/bcp.12311","article-title":"Association between nonsteroidal anti-inflammatory drug use and brain tumour risk: a meta-analysis","volume":"78","author":"Y Liu","year":"2014","journal-title":"British journal of clinical pharmacology"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial","volume":"294","author":"NR Cook","year":"2005","journal-title":"Jama"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1940-6207.CAPR-11-0274","article-title":"Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort","volume":"4","author":"SE Daugherty","year":"2011","journal-title":"Cancer prevention research (Philadelphia, Pa"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/bjc.2013.87","article-title":"Use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs and risk of glioma: a case-control study","volume":"108","author":"D Gaist","year":"2013","journal-title":"British journal of cancer"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/aje\/kwh153","article-title":"Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme","volume":"159","author":"NR Sivak-Sears","year":"2004","journal-title":"American journal of epidemiology"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"E1031","DOI":"10.1002\/ijc.27536","article-title":"HMG CoA reductase inhibitors, NSAIDs and risk of glioma","volume":"131","author":"JS Ferris","year":"2012","journal-title":"International journal of cancer"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1055-9965.EPI-07-2621","article-title":"Long-term anti-inflammatory and antihistamine medication use and adult glioma risk","volume":"17","author":"ME Scheurer","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"ref42","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ijc.25883","article-title":"Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies","volume":"129","author":"ME Scheurer","year":"2011","journal-title":"International journal of cancer"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/sj.bjc.6600945","article-title":"Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study","volume":"88","author":"HT Sorensen","year":"2003","journal-title":"British journal of cancer"},{"issue":"5","key":"ref44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6600760","article-title":"A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin","volume":"88","author":"S Friis","year":"2003","journal-title":"British journal of cancer"},{"issue":"9084","key":"ref45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","article-title":"The UK General Practice Research Database","volume":"350","author":"T Walley","year":"1997","journal-title":"Lancet"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","article-title":"Validity of the general practice research database","volume":"23","author":"SS Jick","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"572","key":"ref47","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3399\/bjgp10X483562","article-title":"Validity of diagnostic coding within the General Practice Research Database: a systematic review","volume":"60","author":"NF Khan","year":"2010","journal-title":"Br J Gen Pract"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"DN Louis","year":"2007","journal-title":"Acta neuropathologica"},{"key":"ref49","article-title":"Diabetes, use of antidiabetic drugs, and the risk of glioma","author":"C Seliger","year":"2015","journal-title":"Neuro-oncology"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1124\/jpet.104.076877","article-title":"Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity","volume":"312","author":"JK Gierse","year":"2005","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"13","key":"ref51","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"TD Warner","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1\u20132","key":"ref52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijpharm.2014.07.028","article-title":"New celecoxib multiparticulate systems to improve glioblastoma treatment","volume":"473","author":"M Vera","year":"2014","journal-title":"International journal of pharmaceutics"},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/00000542-199711000-00016","article-title":"Opioid effects on mitogen-activated protein kinase signaling cascades","volume":"87","author":"HB Gutstein","year":"1997","journal-title":"Anesthesiology"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.yexcr.2009.04.002","article-title":"delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation","volume":"315","author":"A Heiss","year":"2009","journal-title":"Experimental cell research"},{"key":"ref55"},{"issue":"9","key":"ref56","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/pds.1454","article-title":"Using prescription claims data for drugs available over-the-counter (OTC)","volume":"16","author":"MU Yood","year":"2007","journal-title":"Pharmacoepidemiology and drug safety"},{"issue":"21","key":"ref57","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.1158\/0008-5472.CAN-09-1669","article-title":"Height, body mass index, and physical activity in relation to glioma risk","volume":"69","author":"SC Moore","year":"2009","journal-title":"Cancer research"},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bjc.6604445","article-title":"Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort","volume":"99","author":"VS Benson","year":"2008","journal-title":"British journal of cancer"},{"key":"ref59","unstructured":"2011 UKC. United Kingdom population by ethnic group. UK: Office for national Statistics Newport."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0149293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:49:29Z","timestamp":1589024969000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0149293"}},"subtitle":[],"editor":[{"given":"John","family":"Wallace","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0149293","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}